AUG 2 2 2003 WILL

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Hon. Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on this 18th day of August, 2003.

Ву _

(Signature of person mailing Janice Denison

(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Stephanie K. Hall, et al.

APPLICATION NO.: 10/032,242 : Examiner: Chakrabarti, A.K.

FILING DATE: 12/21/2001 : Group Art Unit: 1634

TITLE: Methods and Reagents for Detecting Increased: Risk of Developing an Inflammatory Disorder

Hon. Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

Patent Application Attorney Docket No.PC11026AJAK

A prompt and favorable response is earnestly solicited.

Respectfully submitted,

Gregory P. Raymer Attorney for Applicant(s)

Reg. No. 36,647

Pfizer Inc.
Patent Department, MS 8260-1611
Eastern Point Road
Groton, Connecticut 06340
(860) 715-5746

INFORMATION DISCLOSURE CITATION							ry. Doc	KETN	O. PC1102	SERIAL NO. 10/032,242				
(U	lse sev	eral sh	eets if	necessa	ary)	AP	PLICAN	T Ste	ephanie K.	Hall				_
							FILING DATE 12/21/2001				GROUP 1634			
						U.S	PATEN	IT DOC	UMENTS			г		
MINER ITIAL	DOCUMENT NUM								DATE	NAME	CLASS	SUBCLASS	FILING DAT IF APPROPRI	
	us	6	1	4	0	0	4	7	10/31/00	Duff, et al	435	6		
										-				
	-													
								ļ	 			· · · · · · · · · · · · · · · · · · ·	}	
	-						·						 	_
													ļ	
		ļ			ì						Ì		ļ	
						FORE	GN PAT	ENT D	OCUMENT	s				
			DO	CUMENT N	JMBER				DATE	COUNTRY	CLASS	SUBCLASS	TRANS	LAT
										YES				
	wo	9	8	5	4	3	5	9	12/03/98	Internation	al C12Q	1/68	×	
	WO				 		-	1-3	12/03/90	internation	al Olza	1700	 ^ -	-
		_		 	ļ			 	-			 	 	-
			-		 		 	 	1				<u> </u>	L
			<u></u>		<u> </u>								ļ	
												_		
	<u></u>		ОТН	ER DO	CUMEN	TS (In	cluding A	Author,	Title, Date,	Pertinent Pa	ages, Etc.)			
		1		ıl., 'Cytok	ine gene p	olymorp	hism in hu	ıman dise	ase: on-line d	atabases, Supp	olement 1', Genes	and Immur	nity, Vo	l. 2
		61-70, 2001 Cox, A., et al., 'An analysis of linkage disequilibrium in the Interleukin-1 gene cluster, using a novel grouping method for multiallelic												
_	_	marke	ers', <u>Am.</u>	J. Hum. (Senet., Vo	. 62: 11	80-11 <u>88,</u> 1	998			———————		mana	
		di Giovine, F., et al., 'Novel genetic association of an IL-1B gene variation at +3953 with IL-1B protein production and psoriasis, Cytokine, Vol. 7(6):606, 1995												
		Guasch, J., et al., 'Five novel intragenic dimorphisms in the human Interleukin-1 genes combine to high informativity', Cytokine, Vo. 8(8): 598-602, 1996												
		Reich, K., et al. 'Promoter polymorphisms of the genes encoding tumor necrosis factor-a and Interleukin-1ß are associated with different subtypes of psoriasis characterized by early and late disease onset', <u>Journal of Investigative Dermatology</u> , Vol. 118(1): 1-163, 2002												
											··			
AMINE	ER							DATE	CONSIDERE	D				